Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,836 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C. McGregor B, et al. Among authors: lee ch. Eur Urol Oncol. 2023 Jun;6(3):339-348. doi: 10.1016/j.euo.2023.01.012. Epub 2023 Feb 25. Eur Urol Oncol. 2023. PMID: 36842942 Free article.
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma.
Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang KC, Redzematovic A, Coskey DT, Stewart C, Pradhan N, Arnold AG, Hakimi AA, Chen YB, Coleman JA, Hyman DM, Ladanyi M, Cadoo KA, Walsh MF, Stadler ZK, Lee CH, Feldman DR, Voss MH, Robson M, Motzer RJ, Offit K. Carlo MI, et al. Among authors: lee ch. JAMA Oncol. 2018 Sep 1;4(9):1228-1235. doi: 10.1001/jamaoncol.2018.1986. JAMA Oncol. 2018. PMID: 29978187 Free PMC article.
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY, Mota JM, Whiting KA, Li HA, Funt SA, Lee CH, Solit DB, Al-Ahmadie H, Milowsky MI, Balar AV, Pietzak E, Dalbagni G, Bochner BH, Ostrovnaya I, Bajorin DF, Rosenberg JE, Iyer G. Teo MY, et al. Among authors: lee ch. Eur Urol. 2020 Dec;78(6):907-915. doi: 10.1016/j.eururo.2020.07.018. Epub 2020 Aug 1. Eur Urol. 2020. PMID: 32753285 Free PMC article.
Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing.
Truong H, Sheikh R, Kotecha R, Kemel Y, Reisz PA, Lenis AT, Mehta NN, Khurram A, Joseph V, Mandelker D, Latham A, Ceyhan-Birsoy O, Ladanyi M, Shah NJ, Walsh MF, Voss MH, Lee CH, Russo P, Coleman JA, Hakimi AA, Feldman DR, Stadler ZK, Robson ME, Motzer RJ, Offit K, Patil S, Carlo MI. Truong H, et al. Among authors: lee ch. Eur Urol Oncol. 2021 Dec;4(6):993-1000. doi: 10.1016/j.euo.2021.09.005. Epub 2021 Oct 12. Eur Urol Oncol. 2021. PMID: 34654685 Free PMC article.
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH, Tomita Y, Voss MH, Plimack ER, Choueiri TK, Rini BI, Hammers HJ, Escudier B, Albiges L, Huo S, Del Tejo V, Stwalley B, Atkins MB, McDermott DF. Regan MM, et al. Among authors: lee ch. Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10. Clin Cancer Res. 2021. PMID: 34759043 Free PMC article.
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
Carlo MI, Attalla K, Mazaheri Y, Gupta S, Yildirim O, Murray SJ, Coskey DT, Kotecha R, Lee CH, Feldman DR, Russo P, Patil S, Motzer RJ, Coleman JA, Durack JC, Chen YB, Akin O, Ari Hakimi A, Voss MH. Carlo MI, et al. Among authors: lee ch. Eur Urol. 2022 Jun;81(6):570-573. doi: 10.1016/j.eururo.2022.01.043. Epub 2022 Feb 17. Eur Urol. 2022. PMID: 35183395 Free PMC article. Clinical Trial.
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Lee CH, et al. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17. J Clin Oncol. 2022. PMID: 35298296 Free PMC article. Clinical Trial.
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. Choueiri TK, et al. Among authors: lee ch, lee cw. J Immunother Cancer. 2022 Nov;10(11):e005780. doi: 10.1136/jitc-2022-005780. J Immunother Cancer. 2022. PMID: 36328377 Free PMC article. Clinical Trial.
10,836 results
You have reached the last available page of results. Please see the User Guide for more information.